News | October 21, 2013

FDA Recall: Bard LifeStent Solo Vascular Stent May Fail to Deploy

stents peripheral artery disease pad devices fda lifestent solo vascular bard

October 21, 2013 — Bard Peripheral Vascular has sent an urgent Class I medical device recall notification letter informing customers of the problems of the LifeStent Solo vascular stent and the actions customers should take. The LifeStent Solo vascular stent is an implantable self-expanding stent and delivery system used to improve the superficial femoral artery (SFA) luminal diameter in the treatment of atherosclerotic lesions.

The FDA reported the deployment mechanism for the device may not perform properly when used. Deployment issues range from failure to deploy, partial deployment and difficult deployment. This product may cause serious adverse health consequences, including possible complications of bleeding, loss of limb, heart attack, stroke, vascular surgery and/or death.

Customers were instructed to do the following:

  • Complete the Recall and Effectiveness Check Form (even if they no longer have the recalled product) and fax form to Bard Peripheral Vascular at 1-800-994-6772; and
  • Call Bard Peripheral Vascular’s recall coordinator at 1-800-321-4254 to receive a Return Authorization Number or Consignment Recall Number.


For more information: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=122212

Related Content

FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD) | September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD) | September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD) | September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD) | August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD) | August 02, 2017
Aug.
Sponsored Content | Videos | Peripheral Artery Disease (PAD) | July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD) | July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
Overlay Init